Split Decision In Breach-of-Contract Battle Of Litigation War Between ChromaDex, Elysium
Consolidated Advertising Complaints Continue, ChromaDex Appeals Patent-Infringement Loss
California federal court jury found both breached contracts: Elysium failed to pay for nicotinamide riboside and pterostilbene it ordered and received, while ChromaDex violated pricing provision in supply agreement.
You may also be interested in...
Tru Niagen products available at 3,800 US Walmart stores include a lower dose, 100 mg, that ChromaDex didn't previously market. Launch sparks heavy trading driving up firm's share price.
ChromaDex Corp. agrees to supply its ‘healthy aging’ nicotinamide riboside ingredient Niagen to New York-based healthcare technology firm Roman Health Ventures, Inc., which plans to use it in its men’s supplement line. ChromaDex’ total sales in the first quarter rose 2% to $14.7m.
Tru Niagen supplement firm names Fadi Karam CMO a little more than a month after it announced a distribution deal to put its nicotinamide riboside supplement on shelves at US Walmart stores.